Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00405093 · ClinicalTrials.gov registry record

Aprotinin Use and Renal Outcome in Hypothermic Bypass and Circulatory Arrest for Surgical Repair of Thoracic Aorta.

A clinical trial, sponsored by Weill Medical College of Cornell University.

Completed
Registry status
1,250
Enrollment target

NCT00405093 is a clinical trial that has completed, run by Weill Medical College of Cornell University. The registered enrollment target is 1,250 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00405093 has completed, sponsored by Weill Medical College of Cornell University.

COMPLETED
Registry status
1,250 participants
Enrollment target

Study Summary

Primary Objective: The aim of this study is to assess the effects of Aprotinin (an antifibrinolytic drug used to reduce bleeding during cardiac surgery) on renal function in patients undergoing surgery with use of hypothermic bypass and circulatory arrest for repair of the thoracic aorta. Secondary Objective: To compare the effects of Aprotinin and Amicar on major vascular outcomes following thoracic aorta surgery with use of hypothermic bypass and circulatory arrest.

Trial Details

FieldValue
Enrollment Target 1,250 participants
Start Date 2006-07
Est. Completion 2013-05

What the Registry Record Tells You About NCT00405093

The ClinicalTrials.gov registry entry for NCT00405093 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 1,250 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Weill Medical College of Cornell University, which has 701 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 0 interventions.

NCT00405093 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT00405093 about?

NCT00405093 is a clinical study titled "Aprotinin Use and Renal Outcome in Hypothermic Bypass and Circulatory Arrest for Surgical Repair of Thoracic Aorta.". Primary Objective: The aim of this study is to assess the effects of Aprotinin (an antifibrinolytic drug used to reduce bleeding during cardiac surgery) on renal function in patients undergoing surgery with use of hypothermic bypass and circulatory arrest for repair of the thoracic aorta. Secondary...

What is the current status of trial NCT00405093?

This trial is currently completed. The enrollment target is 1,250 participants. The study started on 2006-07. Estimated completion is 2013-05.

Who is sponsoring clinical trial NCT00405093?

This trial is sponsored by Weill Medical College of Cornell University, which has 701 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.